HK Stock Market Move | JINHAI MED TECH (02225) rose over 5% as its revenue in the first half of the year increased more than 1.3 times year-on-year, shifting its strategic focus towards the high-value-added medical device sector.

JINHAI MED TECH (02225) rose over 5%, and as of the time of publication, it was up 4.08%, trading at HKD 4.72, with a trading volume of HKD 6.2874 million. On the news front, JINHAI MED TECH recently disclosed its mid-year results for 2026. From the operational perspective, the company's revenue growth has accelerated, and the quality of earnings has improved concurrently. In the first half of 2026, the group achieved revenue of SGD 34.021 million, representing a significant year-on-year increase of 134.16%, demonstrating strong sales growth momentum. On the business front, in the first half of 2026, the company's revenue structure has been significantly optimized, with the strategic focus successfully shifting from traditional labor services to the high-value-added medical device sector. Revenue from minimally invasive surgery solutions, medical products, and related service fees now accounts for 74.73%, becoming a new pillar of revenue. Following good growth in medical device sales in 2025, revenue from this segment surged by 301.5% year-on-year in the first half of 2026, reaching SGD 25.427 million, providing ample sustainable growth momentum.